WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319612
CAS#: 402567-16-2
Description: Firategrast, also known as SB-683699 or T-0047, is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). This could decrease multiple sclerosis (MS) activity, but may compromise CNS immune surveillance. The integrins are a sort of transmembrane receptors that modulate the signal transduction from ECM to the cell. They are associated with a lot of diseases such as cancer, inflammation and thrombotic diseases.
MedKoo Cat#: 319612
Name: Firategrast
CAS#: 402567-16-2
Chemical Formula: C27H27F2NO6
Exact Mass: 499.1806
Molecular Weight: 499.5108
Elemental Analysis: C, 64.92; H, 5.45; F, 7.61; N, 2.80; O, 19.22
Synonym: SB-683699; SB 683699; SB683699; T-0047; T 0047; T0047; Firategrast
IUPAC/Chemical Name: (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid
InChi Key: YLFZHHDVRSYTKT-NRFANRHFSA-N
InChi Code: InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1
SMILES Code: O=C(O)[C@@H](NC(C1=C(F)C=CC=C1F)=O)CC2=CC=C(C3=C(OC)C=C(COCC)C=C3OC)C=C2
1: Halland N, Blum H, Buning C, Kohlmann M, Lindenschmidt A. Small Macrocycles As
Highly Active Integrin α2β1 Antagonists. ACS Med Chem Lett. 2014 Jan
10;5(2):193-8. doi: 10.1021/ml4004556. eCollection 2014 Feb 13. PubMed PMID:
24900800; PubMed Central PMCID: PMC4027761.
2: Lu E, Wang BW, Alwan S, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H. A
review of safety-related pregnancy data surrounding the oral disease-modifying
drugs for multiple sclerosis. CNS Drugs. 2014 Feb;28(2):89-94. doi:
10.1007/s40263-013-0131-5. Review. PubMed PMID: 24343726.
3: Grove RA, Shackelford S, Sopper S, Pirruccello S, Horrigan J, Havrdova E, Gold
M, Graff O. Leukocyte counts in cerebrospinal fluid and blood following
firategrast treatment in subjects with relapsing forms of multiple sclerosis. Eur
J Neurol. 2013 Jul;20(7):1032-42. doi: 10.1111/ene.12097. Epub 2013 Feb 18.
PubMed PMID: 23419064.
4: Prat A, Stüve O. Firategrast: natalizumab in a pill? Lancet Neurol. 2012
Feb;11(2):120-1. doi: 10.1016/S1474-4422(11)70306-4. Epub 2012 Jan 5. PubMed
PMID: 22226930.
5: Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua
P, Yousry T, Macmanus D, Montalban X. Firategrast for relapsing remitting
multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled
trial. Lancet Neurol. 2012 Feb;11(2):131-9. doi: 10.1016/S1474-4422(11)70299-X.
Epub 2012 Jan 5. PubMed PMID: 22226929.
